N-acetylcysteine in the treatment of substance use disorders
- 1 January 2020
- journal article
- editorial
- Published by Kare Publishing in Dusunen Adam the Journal of Psychiatry and Neurological Sciences
- Vol. 33 (1), 1-7
- https://doi.org/10.14744/dajpns.2019.00055
Abstract
N-acetylcysteine (NAC) is an agent best known for its clinical efficacy in bronchopulmonary disorders due to its mucolytic properties, and in the treatment of acetaminophen overdose. Given the strong clinical evidence from animal studies of its critical role in regulating glutamatergic receptors, NAC has also been the subject of research related to several psychiatric disorders as a promising treatment approach. This editorial is a brief discussion of the characteristics of NAC and its place in substance use disorders and other psychiatric disorders.Keywords
This publication has 54 references indexed in Scilit:
- Glutamatergic medications for the treatment of drug and behavioral addictionsPharmacology Biochemistry and Behavior, 2012
- New medications for drug addiction hiding in glutamatergic neuroplasticityMolecular Psychiatry, 2011
- Repeated N-Acetyl Cysteine Reduces Cocaine Seeking in Rodents and Craving in Cocaine-Dependent HumansNeuropsychopharmacology, 2010
- Using glutamate homeostasis as a target for treating addictive disordersBehavioural Pharmacology, 2010
- Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addictionEuropean Journal of Pharmacology, 2010
- AMPA Receptor Synaptic Plasticity Induced by Psychostimulants: The Past, Present, and Therapeutic FutureNeuron, 2010
- N‐Acetylcysteine (NAC) in Young Marijuana Users: An Open‐Label Pilot StudyThe American Journal on Addictions, 2010
- Glutamate transmission in addictionNeuropharmacology, 2009
- N-Acetylcysteine Reduces Extinction Responding and Induces Enduring Reductions in Cue- and Heroin-Induced Drug-SeekingBiological Psychiatry, 2008
- Glutamatergic substrates of drug addiction and alcoholismBiochemical Pharmacology, 2008